Gossamer Bio filings document a clinical-stage biopharmaceutical issuer centered on seralutinib for PAH and PH-ILD. Form 8-K reports cover operating and financial results, Phase 3 PROSERA clinical disclosures, material agreements, unregistered equity issuances, resource-allocation actions, and Nasdaq listing-compliance notices involving its common stock.
Proxy materials describe board governance, shareholder voting matters, executive compensation, equity awards, and incentive-plan administration. The filing record also documents capital-structure matters and formal disclosures connected to a late-stage pulmonary hypertension development company.
Gossamer Bio, Inc. reported that Chief Medical Officer Richard Aranda had a one-time repricing of certain outstanding stock options effective March 19, 2026. A series of existing options were surrendered back to the company and replaced with new options covering the same numbers of shares, but with a reduced exercise price of $0.45 per share.
According to the disclosure, all other terms and conditions of the repriced options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on his ongoing service with the company.
Gossamer Bio, Inc. executive Caryn Peterson, EVP of Regulatory Affairs, reported a one-time repricing of multiple stock option awards effective March 19, 2026. Previously granted options were surrendered back to the company and replacement options for the same share amounts were granted with a reduced exercise price of $0.45 per share. According to the disclosure, all other terms of these options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on her ongoing service.
Gossamer Bio Chief Commercial Officer option repricing: Gossamer Bio, Inc. adjusted stock option awards held by Chief Commercial Officer Robert Paul Smith Jr. Effective as of March 19, 2026, the company approved a one-time repricing of certain outstanding options, lowering their exercise price to $0.45 per share while keeping vesting schedules and terms unchanged. Two existing option grants for 562,500 and 572,000 shares of common stock were disposed of back to the issuer at prior exercise prices of $2.88 and $1.13 per share, and replacement options for the same respective share amounts were granted at the new $0.45 exercise price under the 2019 Incentive Award Plan.
Gossamer Bio, Inc. reported that President & CEO Faheem Hasnain had several existing stock option awards surrendered to the company and replaced as part of a one-time repricing effective on March 19, 2026. The repricing reduced the exercise price of each affected option grant to $0.45 per share while keeping all other terms, including vesting schedules and expiration dates, unchanged under the company’s 2019 Incentive Award Plan. Individual grants include, for example, 1,680,000 stock options now exercisable at $0.45 per share expiring in 2036. These are compensation-related derivative transactions rather than open-market share purchases or sales.
Gossamer Bio, Inc. reported that COO/CFO Bryan Giraudo had several existing stock option awards canceled and reissued as part of a one-time option repricing under the company’s 2019 Incentive Award Plan.
The repricing, effective March 19, 2026, reduced the exercise price of these options to $0.45 per share from prior exercise prices ranging from $0.838 to $2.88, while keeping all other terms, including vesting schedules and option terms, unchanged. These are compensation-related derivative transactions and do not involve open-market purchases or sales of common stock.
Gossamer Bio EVP Christian Waage reported a one-time stock option repricing and related option grants and cancellations. Effective as of March 19, 2026, the company approved an option repricing that reduced the exercise price of certain outstanding options to $0.45 per share under its 2019 Incentive Award Plan.
On that date, Waage received multiple new stock option awards with an exercise price of $0.45 covering an aggregate of 2,065,584 shares of common stock, while an equal number of higher-priced options with exercise prices ranging from $0.838 to $2.88 per share were surrendered to the issuer.
All other terms of the repriced options, including vesting schedules and expiration dates through 2036, remain in effect and continue to be tied to Waage’s ongoing service with Gossamer Bio.
Gossamer Bio, Inc. filed a Post-Effective Amendment (POS AM) converting its shelf registration to a non-automatic Form S-3 and provides a prospectus for the offering of up to $200.0 million of common stock, preferred stock, debt securities, warrants and units, to be sold from time to time after the effective date. The prospectus states that specific terms and amounts will be set in prospectus supplements and that offerings may be made through underwriters, dealers, agents or directly. The prospectus also discloses clinical updates: Phase 3 PROSERA topline showed a placebo-adjusted improvement in 6MWD of 13.3 meters (p = 0.0320), which missed the prespecified alpha of 0.025; the company plans to engage the FDA, including requesting a Type C meeting. Enrollment in the Phase 3 SERANATA study for PH-ILD was paused in February 2026.
Gossamer Bio reported widening losses and a setback in its lead pulmonary hypertension program. For 2025, total revenue was $48.5 million, down from $114.7 million in 2024, while net loss increased to $170.4 million, or $0.75 per share.
The Phase 3 PROSERA trial of seralutinib in pulmonary arterial hypertension narrowly missed its prespecified statistical threshold on the primary endpoint, though several subgroup and secondary measures favored seralutinib. The company paused enrollment in the Phase 3 SERANATA study and implemented a workforce reduction to align spending.
Cash, cash equivalents and marketable securities were $136.9 million at December 31, 2025, and Gossamer expects this to fund operations into the first quarter of 2027. The balance sheet showed total stockholders’ equity turning negative, at -$122.8 million, reflecting accumulated losses.
Gossamer Bio is a clinical-stage biopharma focused on seralutinib, an inhaled kinase inhibitor for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The company aims to become a leader in pulmonary hypertension treatments.
In the Phase 3 PROSERA study in PAH, seralutinib achieved a placebo‑adjusted six‑minute walk distance gain of 13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold, but showed stronger effects in intermediate‑ and high‑risk patients and in connective tissue disease‑associated PAH. Gossamer is analyzing the dataset, engaging the FDA on potential regulatory paths, and advancing NDA‑readiness, with a potential approval action date anticipated by year end 2027 if an NDA is submitted and accepted.
The company entered a global collaboration with Chiesi, from which it will receive $160 million and share U.S. development and commercialization for PAH and PH‑ILD, while Chiesi leads outside the United States and in additional indications. Gossamer has paused enrollment in the SERANATA Phase 3 PH‑ILD trial to reassess strategy and continues open‑label extension studies. It also holds an option on RT234, an inhaled, on‑demand PDE5 inhibitor that could re‑enter clinical development as early as 2027, and is evaluating options to strengthen its capital structure, including its outstanding convertible notes and potential additional financings.